HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wieder, H. A. Articles by Weber, W. A. Search for Related Content PubMed PubMed Citation Articles by Wieder, H. A. Articles by Weber, W. A.

Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagogastric Junction

¹ Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
² Department of Radiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
³ Department of Hematology and Oncology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
⁴ Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size. Methods: Twenty patients with adenocarcinoma of the esophagogastric junction (AEG) were studied by ¹⁸F-FDG PET and CT scans before neoadjuvant chemotherapy, 14 d after the initiation of therapy, and 4 wk after the completion of therapy. Results: The relative change in ¹⁸F-FDG uptake was more than 2 times larger than the decrease in tumor size at all time points (P < 0.01). At 14 d after the initiation of chemotherapy, there was no correlation between the reduction in ¹⁸F-FDG uptake and tumor wall thickness. The change in ¹⁸F-FDG uptake after 14 d of therapy was significantly correlated with the reduction in tumor size after the completion of therapy. Conclusion: In AEG, changes in tumor metabolism are a more sensitive parameter for assessing the effects of chemotherapy than are changes in tumor size. Early changes in metabolic activity predict the subsequent reduction in tumor size.

Key Words: CT • ¹⁸F-FDG PET • esophageal cancer • therapy monitoring

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 7a-8a. [Full Text]  

This article has been cited by other articles:

				J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus PET/CT of Esophageal Cancer: Its Role in Clinical Management RadioGraphics, November 1, 2007; 27(6): 1635 - 1652. [Abstract] [Full Text] [PDF]

				J. L. Port, P. C. Lee, R. J. Korst, Y. Liss, D. Meherally, P. Christos, M. Mazumdar, and N. K. Altorki Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 393 - 400. [Abstract] [Full Text] [PDF]

				W. A. Weber and R. Figlin Monitoring Cancer Treatment with PET/CT: Does It Make a Difference? J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S. [Abstract] [Full Text] [PDF]